UA19813A - Спосіб одержаhhя комплексів включеhhя 7-ізопропоксіізофлавоhу - Google Patents

Спосіб одержаhhя комплексів включеhhя 7-ізопропоксіізофлавоhу

Info

Publication number
UA19813A
UA19813A UA4028162A UA4028162A UA19813A UA 19813 A UA19813 A UA 19813A UA 4028162 A UA4028162 A UA 4028162A UA 4028162 A UA4028162 A UA 4028162A UA 19813 A UA19813 A UA 19813A
Authority
UA
Ukraine
Prior art keywords
isopropoxyisoflavone
preparation
cyclodextrin
inclusion complexes
heptakis
Prior art date
Application number
UA4028162A
Other languages
English (en)
Russian (ru)
Inventor
Штадлер Агнеш
Сейтлі Йожеф
Сейтли Йожеф
Вайсфайлер Віктор
Вайсфайлер Виктор
Варгаі Золтан
Варгаи Золтан
Калон Каталін
Калон Каталин
Гергелі Віра
Гергели Вера
Сютш Тамаш
Original Assignee
Хіноін Дьодьсер Еш Ведьєсеті Термекек Д'Яра Рт
Хиноин Завод фармацевтических и химических продуктов А.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хіноін Дьодьсер Еш Ведьєсеті Термекек Д'Яра Рт, Хиноин Завод фармацевтических и химических продуктов А.О. filed Critical Хіноін Дьодьсер Еш Ведьєсеті Термекек Д'Яра Рт
Publication of UA19813A publication Critical patent/UA19813A/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

+(57) Спосіб одержання комплексів включення 7-ізопропоксиізофлавону, що має формулу , які мають здатність всмоктування у фармакологічно активній концентрації, полягає у взаємодії 7-ізопропокси-ізофлавону з альфа, бета, гамма-циклодекстрином, гептакіс-2,6-0-диметил-або 2-гептакіс-2,3,6-три-0-метил-бета-циклодекстрином, або циклодекстриновим полімером з мол.м.4000 у водному або водно-органічному середовищі. Винахід відноситься до клатрату 7- ізопропоксиізофлавону (іпріфлавону), що може знайти застосування у медицині для лікування остеопорозу та остеомаляції.
UA4028162A 1985-09-10 1986-09-09 Спосіб одержаhhя комплексів включеhhя 7-ізопропоксіізофлавоhу UA19813A (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU853415A HU199444B (en) 1985-09-10 1985-09-10 Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom

Publications (1)

Publication Number Publication Date
UA19813A true UA19813A (uk) 1997-12-25

Family

ID=10963942

Family Applications (1)

Application Number Title Priority Date Filing Date
UA4028162A UA19813A (uk) 1985-09-10 1986-09-09 Спосіб одержаhhя комплексів включеhhя 7-ізопропоксіізофлавоhу

Country Status (16)

Country Link
US (2) US4826963A (uk)
EP (1) EP0214647B1 (uk)
JP (1) JPH0688993B2 (uk)
KR (1) KR900000542B1 (uk)
CN (1) CN1006889B (uk)
AT (1) ATE87319T1 (uk)
CA (1) CA1288424C (uk)
CS (1) CS276944B6 (uk)
DD (1) DD254939A5 (uk)
DE (1) DE3688114D1 (uk)
FI (1) FI86958C (uk)
HU (1) HU199444B (uk)
PL (1) PL261349A1 (uk)
RU (1) RU2022970C1 (uk)
SU (1) SU1757472A3 (uk)
UA (1) UA19813A (uk)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221695A (en) * 1987-12-22 1993-06-22 Glaxo Group Limited Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
SI8810082A8 (en) * 1988-01-18 1995-12-31 Lek Tovarna Farmacevtskih Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine
DE3809808A1 (de) * 1988-03-23 1989-10-05 Hexal Pharma Gmbh & Co Kg Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
JPH02142709A (ja) * 1988-11-24 1990-05-31 Kurita Water Ind Ltd 有害生物防除剤
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
IT1241673B (it) * 1989-10-09 1994-01-27 Istituto Biochimico Italiano Complessi di inclusione di silibinina con ciclodestrina, loro preparazione e composizioni farmaceutiche che li contengono.
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
IT1241079B (it) * 1990-03-23 1993-12-29 Chiesi Farma Spa Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
US5221735A (en) * 1991-02-25 1993-06-22 Hoffmann-La Roche Inc. Cyclodextrin-polyene inclusion complexes
JPH06248193A (ja) * 1993-02-25 1994-09-06 Ensuiko Sugar Refining Co Ltd クロセチン含有着色料
HU212932B (en) * 1993-08-02 1996-12-30 Chinoin Gyogyszer Es Vegyeszet Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition
RU2135176C1 (ru) * 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
US6298558B1 (en) * 1994-10-31 2001-10-09 The Gillette Company Skin engaging member
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
WO1996040262A2 (en) * 1995-06-07 1996-12-19 The Procter & Gamble Company Process for preparing encapsulated water soluble beta-carotene
US5847108A (en) * 1996-03-21 1998-12-08 Fujicco Co., Ltd. Clathrate of isoflavone derivatives and edible composition comprising the same
WO1999044621A1 (fr) * 1998-03-06 1999-09-10 Meiji Seika Kaisha, Ltd. Agents pour prevenir/traiter l'osteoporose
JP4006133B2 (ja) 1999-05-17 2007-11-14 松谷化学工業株式会社 可溶性イソフラボン組成物及びその製造方法
US7182972B2 (en) * 1999-12-17 2007-02-27 Quercegen Pharma, Llc Water-soluble bean-based extracts
JP4413464B2 (ja) 1999-12-17 2010-02-10 光則 小野 水溶性の豆ベース抽出物
US6541062B2 (en) 1999-12-17 2003-04-01 Mitsunori Ono Water-soluble soybean extracts
JP4585074B2 (ja) * 2000-03-28 2010-11-24 ライオン株式会社 薬剤組成物の製造方法
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
DE10211192A1 (de) * 2002-03-14 2003-09-25 Beiersdorf Ag Isoflavanoide gegen Hautalterung und Akne
EP1560503A4 (en) * 2002-11-15 2006-04-05 Cargill Inc COMPOSITIONS BASED ON SOLUBLE ISOFLAVIUM
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
KR100847225B1 (ko) 2003-10-24 2008-07-17 (주)아모레퍼시픽 사이클로 덱스트린의 분자 인식 기능을 이용한이소플라본의 추출방법
AU2007317429B2 (en) * 2006-11-03 2013-03-28 Corn Products Development Inc. Encapsulated soy extracts and process for preparing same
JP4978209B2 (ja) * 2007-01-22 2012-07-18 株式会社イヅツみそ フリーズドライ味噌の製造方法
KR100929920B1 (ko) * 2007-09-05 2009-12-04 주식회사 마크로케어 사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
WO2010058242A1 (en) * 2008-11-24 2010-05-27 Giovanni Nicolao Berta New formulations with anti-neoplastic activity
CN101757640B (zh) * 2009-06-09 2011-08-31 东华大学 一种鹰嘴豆异黄酮与环糊精包合物的制备
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
EP2931287B1 (de) 2012-12-11 2017-10-04 Sapiotec GmbH Delphinidin zur bekämpfung von melanomzellen
CN110325217B (zh) 2017-01-09 2023-08-08 塞法姆公司 制备水溶性毛喉萜的新工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3949085A (en) * 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
HU194858B (en) * 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
DE3485000D1 (de) * 1983-06-28 1991-10-10 Takeda Chemical Industries Ltd Gemahlene mischung.

Also Published As

Publication number Publication date
SU1757472A3 (ru) 1992-08-23
ATE87319T1 (de) 1993-04-15
HU199444B (en) 1990-02-28
FI86958C (fi) 1992-11-10
HUT41759A (en) 1987-05-28
CN86106889A (zh) 1987-07-15
CA1288424C (en) 1991-09-03
FI863652A (fi) 1987-03-11
US5043326A (en) 1991-08-27
EP0214647A3 (en) 1987-09-30
DD254939A5 (de) 1988-03-16
PL261349A1 (en) 1987-06-29
EP0214647B1 (de) 1993-03-24
CN1006889B (zh) 1990-02-21
RU2022970C1 (ru) 1994-11-15
FI863652A0 (fi) 1986-09-10
JPS62103077A (ja) 1987-05-13
KR900000542B1 (ko) 1990-01-31
JPH0688993B2 (ja) 1994-11-09
US4826963A (en) 1989-05-02
FI86958B (fi) 1992-07-31
CS653586A3 (en) 1992-10-14
CS276944B6 (en) 1992-10-14
DE3688114D1 (de) 1993-04-29
EP0214647A2 (de) 1987-03-18
KR870002842A (ko) 1987-04-13

Similar Documents

Publication Publication Date Title
UA19813A (uk) Спосіб одержаhhя комплексів включеhhя 7-ізопропоксіізофлавоhу
ES8504789A1 (es) Procedimiento para la preparacion de compuestos complejos de piroxicam con ciclodestrinas
ATE108771T1 (de) Chelatbildner zur komplexierung von radioaktiven isotopen, deren metallkomplexe sowie ihre verwendung in diagnostik und therapie.
DK0609606T3 (uk)
IE820136L (en) Pharmaceutical formulation
HUT49600A (en) Process for producing substituted flavonoid deriatives and salts, thereof, as well as pharmaceutical compositions comprising such compounds
KR860003830A (ko) 가용화한 백금화합물 및 그 제조방법
HU911928D0 (en) Process for the production of chelates and its complexes containing orto ligating functional group, and the medical preparations containing thereof
CZ16395A3 (en) Inclusion complexes of nimesulid salts of alkali metals and alkaline earth metals with cyclodextrins, process of their preparation and pharmaceutical compositions containing thereof
JO1406B1 (en) Chemical compounds
GR3031114T3 (en) Use of a pregnane derivatives for the treatment of tumours.
EP0194901A3 (en) Isoprenoidamine derivatives, compositions containing them, their preparation, and their use
ATE240108T1 (de) Doxorubicin enthaltende einspritzbare gebrauchsfertige lösungen gegen krebs
AU8069887A (en) Pharmaceutical compositions
HUT44515A (en) Process for producing isoquinolinol compounds of heart activity increasing, phosphodiesterase iii inhibiting and/or renal vasodilating activity and pharmaceutical composition containing them
ATE53004T1 (de) Pharmazeutische zusammensetzungen mit inhalt von 5-phenyl-1,3-dioxoalkenylverbindungen.
ES8706143A1 (es) Procedimiento para la obtencion de benzotiopiranonas
EP0309262A3 (en) Novel salicylates, their salts, pharmaceutical compositions containing them and process for preparing same
ATE69609T1 (de) Cardiotonische imidazolylphenylpyrrol-2-one.
IT1274592B (it) Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
AU577570B2 (en) Mefloquine quinates
GR880100225A (en) New derivatives of rivofurane acid